» Articles » PMID: 30127893

Decreased Expression Level and DNA-binding Activity of Specificity Protein 1 Via Cyclooxygenase-2 Inhibition Antagonizes Radiation Resistance, Cell Migration and Invasion in Radiation-resistant Lung Cancer Cells

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Aug 22
PMID 30127893
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation is able to inhibit tumor growth, promote tumor cell apoptosis and prolong patient survival. However, radiation resistance remains a major impediment to radiotherapy. Local and metastatic recurrences following radiation are still large impediments to overall survival. Although cyclooxygenase-2 (COX-2) inhibitors may induce radiation sensitivity in cancer cells, the underlying mechanisms are not fully understood. The present study demonstrated high potential for cell proliferation, migration and invasion in radiation-resistant lung cancer cell lines. The present study observed the overexpression of specificity protein 1 (Sp1) in these cells, and the overexpression of Sp1 induced upregulation of matrix metalloproteinase (MMP)-2, MMP-9, B cell lymphoma-2, in addition to a high potential for radiation resistance, migration and invasion in these cells. The present study revealed that the COX-2 selective inhibitor, celecoxib, enhanced radiation sensitivity and inhibited migration and invasion in these cells by inhibiting the expression and DNA-binding activity of Sp1. Furthermore, celecoxib downregulated Sp1 by inhibiting c-Jun N-terminal kinase (JNK). Taken together, the present study demonstrated that Sp1 overexpression in radiation-resistant cancer cells and COX-2 inhibitors enhanced radiation sensitivity and inhibited the migration and invasion of cancer cells, at least partially, via inactivation of the JNK/Sp1 signaling pathway and a decrease in Sp1 DNA-binding activity.

Citing Articles

COX-2 in lung cancer: Mechanisms, development, and targeted therapies.

Liu X, Zhang J, Sun W, Cao J, Ma Z Chronic Dis Transl Med. 2024; 10(4):281-292.

PMID: 39429482 PMC: 11483542. DOI: 10.1002/cdt3.120.


The multifaceted roles of matrix metalloproteinases in lung cancer.

Wei C Front Oncol. 2023; 13:1195426.

PMID: 37766868 PMC: 10520958. DOI: 10.3389/fonc.2023.1195426.


The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview.

Barillari G, Melaiu O, Gargari M, Pomella S, Bei R, Campanella V Int J Mol Sci. 2022; 23(15).

PMID: 35955471 PMC: 9369056. DOI: 10.3390/ijms23158336.


The molecular mechanisms of celecoxib in tumor development.

Wen B, Wei Y, Mu L, Wen G, Zhao K Medicine (Baltimore). 2020; 99(40):e22544.

PMID: 33019464 PMC: 7535670. DOI: 10.1097/MD.0000000000022544.


The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process.

Barillari G Int J Mol Sci. 2020; 21(12).

PMID: 32630531 PMC: 7350258. DOI: 10.3390/ijms21124526.


References
1.
Hsu T, Wang M, Chen S, Yeh Y, Su W, Chang W . Sp1 expression regulates lung tumor progression. Oncogene. 2011; 31(35):3973-88. PMC: 3432230. DOI: 10.1038/onc.2011.568. View

2.
Paquette B, Baptiste C, Therriault H, Arguin G, Plouffe B, Lemay R . In vitro irradiation of basement membrane enhances the invasiveness of breast cancer cells. Br J Cancer. 2007; 97(11):1505-12. PMC: 2360264. DOI: 10.1038/sj.bjc.6604072. View

3.
Chuang J, Wang S, Yang W, Yang H, Hung C, Su T . Sp1 phosphorylation by cyclin-dependent kinase 1/cyclin B1 represses its DNA-binding activity during mitosis in cancer cells. Oncogene. 2012; 31(47):4946-59. PMC: 3707305. DOI: 10.1038/onc.2011.649. View

4.
Chiefari E, Brunetti A, Arturi F, Bidart J, Russo D, Schlumberger M . Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?. BMC Cancer. 2002; 2:35. PMC: 139985. DOI: 10.1186/1471-2407-2-35. View

5.
Molina M, Lemoine M, Frazier M, Sinicrope F . Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999; 59(17):4356-62. View